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Abstract.  We report the identification of a novel lami- 
nin variant that appears to be unique to a subset of 
epithelial basement membranes. The variant contains 
two chains electrophoretically and immunologically 
identical to the B1  and B2 chains. Epitopes contained 
in the laminin A chain are absent from the molecule, 
and a  190-kD  chain substitutes for the A chain. V8 
protease analysis and Western blotting studies indicate 
that the variant 190-kD  chain shows  structural and im- 
munological similarity to the 200-kD chain of kalinin. 
Rotary shadowing analysis indicates that the 190-kD 
chain contributes a large globular structure to the vari- 
ant long arm, but lacks the short arm contributed to 
laminin by the A chain. The variant is produced by 
cultured skin explants, human keratinocytes and a 
squamous cell carcinoma line, and is present in human 
amniotic fluid. Polyclonal antibodies raised to kalinin, 
a recently characterized novel component of anchoring 
filaments, and mAb BM165 which recognizes a  sub- 
unit of kalinin (Rousselle et al.,  1991) cross react with 
the variant under nonreducing conditions. Immuno- 
histological surveys of human tissues using the cross- 
reacting antikalinin antiserum indicate that the distri- 
bution of this laminin variant is at least restricted to 
anchoring filament containing basement membranes. 
We propose the name K-laminin for this variant. 
Ar~IrqIN purified  from  the  murine  Engelbreth-Holm- 
Swarm  (EHS) ~ tumor,  is a disulfide-bonded trimer 
consisting of a 400-kD A chain, a 220-kD B1 chain, 
and a 210-kD  B2 chain  (Cooper  et al.,  1981). By rotary 
shadowing EM, EHS laminin has the image of an asymmet- 
ric cross with one long arm and three short arms (Engel et 
al.,  1981). Laminin is a component of all basement mem- 
branes  (Foidart et al.,  1980) 
Fragmentation studies of the large EHS laminin molecule 
have facilitated the localization of several of its properties to 
individual molecular domains. The large size and multido- 
main structure of this molecule give it the potential to span 
the basement membrane, mediate the interactions of multi- 
ple  basement  membrane  components,  and  interact  with 
receptors at basal cell surfaces adjacent to basement mem- 
brane (Beck et al., 1990). Several extracellular matrix pro- 
teins are capable of interacting with EHS laminin, including 
type IV collagen, nidogen, and heparin sulfate proteoglycan 
(Martin  and Timpl,  1987). Of these,  the nidogen-laminin 
complex is  the most stable  (Paulsson et al.,  1987). EHS 
laminin also has the ability to self aggregate (Yurchenco et 
al.,  1985). 
Many types of  cells including keratinocytes (Stanley et al., 
1982) and dermal  fibroblasts (Woodley et al.,  1988) have 
both been shown to synthesize laminin in culture. Some cell 
1. Abbreviations used in this paper: EHS, Engelbreth-Holm-Swarm; KGM, 
keratinocyte growth medium; SCC, squamous cell carcinoma, 
lines, including choriocarcinoma  cells (Peters et al.,  1985) 
and HT 1080 fibrosarcoma cells (Alitalo et al., 1980) syn- 
thesize an excess of B chains relative to A chain.  Pertinent 
to these observations,  recent  in situ hybridization  experi- 
ments of human skin samples has revealed abundant expres- 
sion of B1 and B2 chain genes, but undetectable expression 
of A chain gene (Olsen et al., 1989). It is possible that in 
both skin and cultured cells, B1 and B2 chains are synthe- 
sized in relative excess and that synthesis of A chain serves 
as the rate-limiting step for laminin assembly. 
Additionally, it is becoming increasingly clear that laminin 
chains are assembled into a variety of structures. Merosin is 
a laminin variant which contains a B1 chain, a B2 chain, and 
a third chain distinct from the A chain,  although it shares 
40% homology by sequence analysis (Ehrig et al.,  1990). 
Mouse heart laminin (Paulsson and Saladin, 1989) is a lami- 
nin variant with a substituted A chain of  a size similar to the 
one in merosin. S-laminin, another laminin variant, contains 
a normal A chain, B2 chain, and a variant chain that shows 
some sequence homology to the B1 chain (Hunter et al., 
1989). Recently, the merosin variant chain and the S-laminin 
variant chain have been found complexed together with B2 
in certain tissues, including the myotendonous  junction (Eng- 
vail et al., 1990). Two other laminin variants which appar- 
ently lack an A chain have been reported, but unlike merosin 
and S-laminin, it is not known whether they are present in 
tissue. These include rat RN22 schwannoma laminin (Davis 
et al., 1985; Edgar et al., 1988) and 3T3 adipocyte laminin 
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132 subunits, but lack electrophoretically normal A subunits. 
Thus laminin exists as a family of proteins, and its individual 
members have  restricted tissue distributions,  for example 
merosin and S-laminin localize to muscular and neural base- 
ment membranes,  respectively,  but not to epithelial base- 
ment membranes (Engvall et al.,  1990). 
Laminin  has  been  shown  to  influence  the  growth  and 
differentiation of many types of cells, and is present at the 
earliest stages of human development (Timpl and Dziadek, 
1986). Laminin is also a component of the extracellular ma- 
trix  deposited  by  keratinocytes  onto  culture  substratum 
(Carter et al.,  1990;  Marchisio et al.,  199D.  Exogenously 
supplied EHS laminin facilitates the attachment of a variety 
of epithelial cell types (Terranova et al., 1980; Goodman et 
al.,  1987),  including  human  keratinocytes  (Wilke  and 
Skubitz,  1991) but markedly decreases motility of cultured 
keratinocytes  (Woodley et al.,  1988). 
Anchoring filaments are thin threadlike  structures  which 
localize to the lamina lucida of a subset of basement mem- 
branes (Ellison and Garrod,  1984).  An anchoring filament 
component, kalinin, has recently been described (Rousselle 
et al., 1991).  Kalinin is similar to laminin in that it is a large 
heterotrimeric protein which localizes to the lamina lucida, 
plays a role in cell attachment and is a component of the ma- 
trix  deposited  by  keratinocytes  onto  culture  substratum 
(l~ousselle et al., 1991). It is composed of a disulfide-bonded 
complex of 200-,  155-, and 140-kD suhunits.  In tissue and 
cell culture, the 200-Kd subunit is processed to 165 kD, and 
the 155-kD subunit is processed to 105 kD (Marinkovich et 
al., 1992). The mAb BM165 recognizes the kalinin 200/165- 
kD subunit  (Rousselle et al., 1991) and the recently charac- 
terized mAb K140  recognizes the  kalinin  140-kD  subunit 
(Marinkovich et al.,  1992). 
Previously,  basement membranes at areas  of epithelial- 
mesenchymal interface, such as the one found at the dermal- 
epidermal junction, were believed to contain only laminin of 
the EHS prototype. We show here a subset of epithelial base- 
ment membranes  contain  a  second novel variant  form of 
laminin, in addition to laminin of the EHS prototype.  Skin 
in organ culture and epidermal cells in primary culture pro- 
duce the variant,  which has a "Y" shaped rotary-shadowed 
image. We demonstrate that this variant is composed of a B1 
chain,  a B2  chain, and a third  190-kD  chain which is im- 
munologically distinct from the laminin A chain but immu- 
nologically and structurally  related  to the 200/165-kD  sub- 
unit  of kalinin.  We propose  the  name  K-laminin  for this 
variant. 
Materials and Methods 
Keratinocy~ growth medium (KGM) was purchased from Clonetics Corpo- 
ration (San Diego,  CA). Hydrocortisone,  cholera toxin, and tissue culture 
grade epidermal growth factor were purchased from Sigma Chemical Com- 
pany (St. Louis, MO). Mouse EHS laminin, DME, heat inactivated FBS, 
Ham's F-12 nutrient mixture, and penicillin/streptomycin 100x  solution 
were  purchased  from Gibco Laboratories (Grand Island,  NY).  Rabbit 
anti-mouse IgG immunobeads, goat anti-rabbit  IgG immunobeads, and pre- 
stained high molecular weight markers for electrophoresis were purchased 
from Bio-Red Laboratories (Richmond, CA).  CNBr-activated sepharose 
CI-4B beads were purchased from Pharmacia/LKB (Pleasant Hill, CA). V8 
protease was purchased from ICN Biomedicals, Inc., Irvine, CA.  [35S]- 
cysteine and [3SS]methioaine were purchased from Amersham Corp. (Dan- 
vet's, MA). 
Antibodies 
The mAb BM165 reacts with the 165-kD chain of kalinin, as previously de- 
scribed (Rousselle et al.,  1991). Preparation and specificity of mAb K140 
which reacts with the 140-kD subunit of kaiinin and rabbit polyclonal an- 
tiserum against kaiiain is described elsewhere (Marinkovich et al.,  1992). 
The laminin A chain specific mAbs 11:5, llD5 (EngvaU et al., 1990), 4C'/ 
(Engvail et al., 1986), laminin B2 chain specific mAb 2E8 (Engvall et al., 
1986), and anti merosin mAb 5H2 (Leivo et al., 1989) were kindly provided 
by Dr. Eva Engvall of the La Jolla Cancer Research Foundation.  Affinity- 
purified polyclonal  antibody against mouse laminin was  obtained from 
Sigma Chemical Co. mAbs were purified from hybridoma medium as previ- 
ously described (Keene et aL,  1991). 
During the course of these studies a new mAb, 545, was developed. Anti- 
gen for mAb 545 was obtained from the reduced product of the PF3 fraction 
of human amniotic membrane prepared as previously  described (Maddox 
et al., 1989). Briefly, disulfide bonds of the PF3 fraction were reduced and 
aikylated with vinyl pyridine. Peptides containing cysteine residues were re- 
duced in 100-fold molar excess of 2-mercaptoethanol overnight at room 
temperature in 0.5 M Tris-HCl buffer, pH 7.5, containing 0.2 M NaCI and 
5 mM EDTA.  Equimolar amounts of vinyl pyridine to mercaptoethanol 
were added and after a further 90-min incubation at room temperature,  the 
peptides were separated from excess reagent by gel filtration,  and used for 
immunization of a BALB/c mouse as previously described (Sakai et al., 
1986). mAb 545 has been shown to specifically immunoprecipitate laminin 
from a  complex mixture of proteins in radiotabeled keratinocyte-condi- 
tioned medium (not shown).  Additionally, this antibody has been shown to 
have a staining pattern identical to polyclonai  antilaminin antibody on hu- 
man skin sections by indirect immunofluorescent microscopy  (not shown). 
Cell Culture 
Keratinocytes  were cultured from newborn foreskins by a modification  of 
an established method (Rheinwald and Green, 1975; O'Keefe et al., 1988). 
Before the first passage cultures were incubated in sterile PBS containing 
0.02% EDTA for 5 rain, gently pipetted to remove dermal fibroblasts and 
3T3 cells,  then washed and treated with trypsin 0.05%  and EDTA 0.02% 
wt/vol to suspend keratinocytes.  Subsequently,  cells were grown in KGM 
containing 0.15 mM CaC12 and subcultured according to the manufac- 
turer's instructions. Squamous  cell carcinoma line SCC-25  (ATCC No. 
CRL 1628) was cultured in 50% Ham's F-12 medium, 50% DME with 0.5 
#g/ml hydrocortisone,  and 10% FBS, and was routinely subcultured with 
0.05 % trypsin, 0.02 % EDTA in PBS. 
Cell Labeling 
For 24-h labeling experiments, dissociated third passage keratinocytes were 
allowed  to attach to tissue culture plastic dishes,  5  ￿  105 cells/cm  2,  in 
complete KGM for 2 h. Adherent cells were briefly washed with methionine 
and cysteine-deficient  KGM.  Labeling was performed in deficient  KGM 
containing 50/~Ci/ml each of [35S]methionine and [35S]cysteine for 24 h 
under standard culture conditions. 
In organ culture experiments,  fetal bovine skin was removed from a 10- 
in. (crown to rump length) calf <4 h out of the uterus. Skin was cut into 
1 x  1-nun sections and cultured in suspension for 24 h in methionine- and 
cysteine-deficient  DME  containing hydrocortisone (0.5  ~g/mi)  cholera 
toxin (I0 ng/ml), EGF (10 ng/ml), penicillin (100 U/ml), streptomycin (100 
~g/ml)  FBS  2%,  [35S]methionine  (50  #Ci/ml),  and  [35S]cysteine (50 
#Ci/ml). Subsequently, tissue was washed and incubated in complete non- 
radioactive DME containing the above factors and 10% FBS for 72 h. Ali- 
quots of tissue were removed after the 24-h labeling period and again after 
the 72-h nonradioactive chase period and processed for immunoprecipita- 
tion as described below for celt samples. 
Antibody Precomplexing and 
Radioimmunoprecipitation 
For each sample to be analyzed 10 #g protein-G purified mAb was added 
to 100 #1 rabbit anti-mouse IgG immunobeads or 10/~1 polyclonal  rabbit 
antisera was added to 400 #1 "second antibody  ~ goat anti-rabbit IgG im- 
munobeads. For polyclonai  control conditions 10 #1 normal rabbit serum 
was  used.  For monoclonal control conditions, no primary antibody was 
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antibody-immunobead complexes were pelleted by centrifugation at 2,500 
rpm, washed once with radioimmunoprecipitation assay (RIPA) buffer (10 
mM Tris-HC1,  pH 7.4,  150 mM NaCI, 2 mM EDTA, 250/~M PMSF, I mM 
n-ethylmaleimide, 2  mM  1-methionine, 2  mM  1-cysteine,  0.3%  NP-40, 
0.05%  triton X-100, 0.3% sodium deoxycholate, 0.1% BSA, and repelleted 
before use with labeled sample. 
Cell layers were washed once with nonradioactive culture medium then 
harvested with a cell scraper and ice cold RIPA buffer containing 0.1% SDS. 
All subsequent steps were performed at 4~  Labeled cell material was 
solubilized in a Dounce homogenizer and spun at 14,000  rpm for 10 min. 
Labeled medium was removed from culture and centrifuged at 2,000 rpm. 
Preclearing of each sample was accomplished by adding aliquots of labeled 
cell or medium supernatants to the centrifuged pellets of either 400/~1 goat 
anti-rabbit IgG immunobeads precomplexed with 10/~1 nonimmune rabbit 
serum, or 100/zl rabbit anti-mouse IgG immunobeads. Each sample was 
vortexed briefly, then left on a rocking platform for 1 h. The mixture was 
then centrifuged at 14,000  rpm for 10 rain, and the supernatant combined 
with the centrifuged pellet of immunobeads precomplexed with specific an- 
tibody. Each sample was incubated with specific antibody for 18 h on a rock- 
ing platform, then pelleted by cantrifugation at 2,500 rpm for 10 rain. After 
centrifugation, the supernatant was removed and the pellet was washed with 
RIPA buffer (medium samples) or RIPA buffer containing 0.1% SDS (cells), 
briefly vortexed, then recentrifuged. After five washes, the pellets were 
mixed with sample buffer, heated to 95~  for 3 rnin, recentrifuged, and the 
supernatant was analyzed by SDS-PAGE. In one experiment, kalinin was 
removed from precleared labeled keratinocyte medium by passage over a 
mAb  K140-sepharose  column  before  immunoprecipitation  with  mAb 
BM165. 
ImraunoaJ~fnity Purification of the Laminin Variant 
Human amniotic fluid obtained from first and second trimester amniocente- 
sis or squamous cell carcinoma-conditioned  medium were each centrifuged 
at 1,000 rpm to remove cell debris. Supernatants were brought to 250 t~m 
PMSE  1 mM n-ethylmaleimide, 2 mM EDTA, and 0.02 % sodium azide, 
then centrifuged at  18,000  rpm for 90 min.  The supernatants were then 
passed over either mAb BM165-sepharose (Rousselle et al., 1991), or mAb 
2E8-sepharose columns (1 mg antibody per 1 mi matrix, coupled to CL4B 
sepharose per manufacturer's instructions)  (Pharmacia  Fine  Chemicals, 
Pleasant Hill, CA), washed with 50 column volumes PBS, then eluted with 
1 M  acetic acid. Peak fractions were determined by UV 280 absorbance 
and Western blotting, treated with diisopropyl fluorophosphate (5/zg/ml), 
and dialyzed against water. Samples for rotary shadowing analysis were dia- 
lyzed against 0.2 M ammonium bicarbonate and concentrated fivefold on 
a centricon-30 microconcentrator (Amicon, Beverly,  MA). 
Other Methods 
The following procedures were performed as previously described: SDS- 
PAGE (Laemmli,  1970),  electrophoretic transfer of proteins to nitrocellu- 
lose with immunoblot analysis (Lunstrum et al.,  1986),  visualization of 
rotary-shadowed images by EM (Morris et al., 1986), indirect immunofluo- 
rescent microscopy of frozen sections of human tissue (Sakai  et al., 1986), 
fluorography of acrylamide gels containing radioactive proteins (Bonner 
and Laskey, 1974),  and V8 protease digestion of excised gel bands (Cleve- 
land et al.,  1977). 
Results 
Biosynthetically radiolabeled keratinocyte-conditioned cul- 
ture medium was immunoprecipitated using several antibod- 
ies.  Polyclonal anti-EHS  laminin specifically precipitates 
two electrophoretic species before disulfide bond reduction 
(Fig.  1, lane/).  No bands are precipitated from the same 
medium in the absence of primary antibody (Fig. 1, lane 8). 
The  same two electrophoretic  species are precipitated by 
monoclonal antilaminin B2 chain antibody 2E8 (Fig. 1, lane 
2). In contrast, monoclonal antilaminin A chain antibodies 
IF5,  4C7,  and  11D5, precipitate  only  the  slower  elec- 
trophoretic species (Fig.  1, lanes 3, 4, and 5, respectively). 
Figure 1.  Nonreduced immunoprecipitation of keratinocyte me- 
dium using various antibodies. Human keratinocyte-conditioned 
medium derived from a 24-h radiolabeling  period was immunopre- 
cipitated with the following  antibodies: lane 1, polyclonal  antilami- 
nin; lane 2, 2E8 (monoclonai antilaminin B2 chain); lane 3,  1F5 
(monoclonal antilaminin A chain); lane 4, 4C'/ (monoclonal an- 
tilaminin A chain); lane 5, I1D5 (monoclonal  antilaminin A chain); 
lane 6, BM165 (monoclonal antikalinin 200/165-kD chain); lane 7, 
BM165 immunoprecipitation  of medium which has been cleared of 
kalinin by mAb K140 (monoclonal  antikalinin 140-kD chain); lane 
8, control (no primary antibody); and lanes 9 and 10, medium se- 
quentiaily immunoprecipitated, first with 4C7  monoclonal an- 
tilaminin A chain (lane 9) then with polyclonal antilaminin (lane 
10). Samples were analyzed by nonreduced SDS-PAGE on 3-5% 
acrylamide gradient gels and visualized by autoradiography. L, 
laminin;  V,  variant; and K, kalinin. Right margin indicates Mr 
x  10  -3. 
mAb BM165 coprecipitates kalinin and the faster migrating 
species (Fig.  1, lane 6). The mAb K140 precipitates kalinin 
but  not  the  laminin  variant  from  labeled  keratinocyte 
medium (not shown). When kalinin is precleared from la- 
beled medium with an excess of K140, BM165 only precipi- 
tates the faster migrating laminin variant (Fig.  1,  lane 7). 
Given the characterized specificity of the immunological re- 
agents, the results suggest that human keratinocytes secrete 
a lower molecular weight variant of laminin containing at 
least a B2 chain, but not a normal A chain. These results also 
show that mAb BM165 cross reacts with the faster-migrating 
laminin species, suggesting that immunologically  the variant 
chain  contained  in  this  laminin  species  is  more  closely 
related to the kalinin 200/165-kD chain than to the laminin 
A chain. Antimerosin mAb 5H2 failed to precipitate either 
species from keratinocyte medium (not shown) consistent 
with the absence  of merosin  from the  dermal-epidermal 
basement membrane  of human  skin  (Leivo and  Engvall, 
1988). 
To further verify the identity of the faster electrophoretic 
species  as  a  laminin  variant,  radiolabeled  keratinocyte 
medium was precleared of normal laminin using antilaminin 
A  chain antibody and then reprecipitated using polyclonal 
antilaminin serum. The anti-A chain antibody removes only 
laminin, leaving the variant which is specifically removed by 
the polyclonal serum plus a  small amount of conventional 
laminin (Fig.  1, lanes 9 and 10). 
When the antilaminin immunoprecipitation product from 
keratinocytes medium fractions (Fig. 2, lane/) is compared 
with that of keratinocyte cell fractions (Fig. 2,  lane 2) by 
nonreduced SDS-PAGE, it is apparent that after a 24-h label- 
ing period, there is a greater fraction of laminin (Fig. 2, L) 
present in the cell fraction, than in the medium fraction. The 
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fractions. Following a 24-h metabolic labeling period,  keratino- 
cyte-conditioned medium (lanes 1 and 3), and keratinocyte cell 
fraction (lanes 2 and 4), were each immunoprecipitated with poly- 
clonal antilaminin. Precipitated materials were then separated by 
nonreduced SDS-PAGE  on a 3-5 % gradient gel (lanes I and 2) and 
separated by reduced SDS-PAGE  on a 5 % acrylamide gel (lanes 3 
and 4). Nonreduced gel bands containing the variant (V, lane 1 ) 
and laminin (L, lane 1 ) were excised from the dried gel, rehydrated 
with sample buffer containing 2 % 2-mercaptoethanol,  and sepa- 
rated by second dimension reduced SDS-PAGE  on a 5 % acrylamide 
gel; variant band (lane 5), laminin band (lane 6). All samples were 
visualized by fluorography. Right margins indicate Mr  ￿  10  -3. 
cell fraction also contains a strong 400-kD band (Fig. 2, d) 
which reduces to a pair of bands at 220-210 kD (not shown). 
This 400-kD  band is  therefore interpreted to be a  B1-B2 
chain dimer, whose existence has been previously proposed 
(Cooper et  al.,  1981;  Morita  et al.,  1985;  Peters  et  al., 
1985).  No  laminin  A  chain  was  detected  in  the  second 
dimension analysis of the 400-kD band (not shown). 
Reduction  of the  medium  derived  immunoprecipitates 
(Fig. 2, lane/) clearly shows the predominance of bands in 
the positions of the laminin B1 and B2 chains, and in the 190- 
kD position (Fig. 2, lane 3).  Consistent with the presence 
of a minor amount of laminin, only small amounts of laminin 
A chain are seen. In contrast, reduction of the cell-derived 
materials (Fig. 2, lane 4) shows  amounts of A, B1, B2, and 
190-kD chains expected from a nearly equal mixture of lami- 
nin and the variant indicated by the unreduced gel pattern 
(Fig. 2, lane 2). The pattern of bands of apparent molecular 
weight <190 kD in lanes 3 and 4 are identical to those of con- 
trol  samples  where  no  primary  antibody  was  used  (not 
shown). 
When the nonreduced variant gel band (Fig. 1, lane 1, band 
V)  is  excised and  analyzed by SDS-PAGE after disulfide 
bond reduction (Fig. 2, lane 5), a broad band containing the 
B chains and a distinct 190-kD band are present. Alterna- 
tively, when the nonreduced laminin gel band is  similarly 
treated, a 400-kD A chain and no 190-kD band are observed 
(Fig. 2, lane 6). Together with the results presented in Fig. 
1,  these data indicate that the variant does contain chains 
electrophoretically identical to both the B1 and B2 chains, 
and contains a third chain of 190 kD that is not immunoreac- 
tive with three mAbs each directed toward different epitopes 
within the A chain, but which is reactive to a mAb directed 
against the 200/165-kD subunit of kalinin. 
Organ culture studies with fetal bovine skin reveal that af- 
ter  a  24-h  labeling  period,  the  nonreduced  pattern  of 
Figure  3.  Laminin  biosynthesis  in 
skin organ culture. Fetal bovine skin 
in suspension culture was metaboli- 
cally labeled for 24 h then analyzed 
immediately (lane 1 ) or analyzed af- 
ter an additional 72-h period of cul- 
ture in nonradioactive medium (lane 
2).  Samples were  immunoprecipi- 
rated with polyclonal antilaminin an- 
tibody,  separated  by  nonreduced 
SDS-PAGE on a 3-5%  acrylamide 
gradient gel, then visualized by auto- 
radiography. Right margin indicates 
Mr  x  10  -3.  L,  laminin;  E  variant; 
and d, dimer. 
materials immunoprecipitated with polyclonal laminin an- 
tisera from cultured skin (Fig. 3, lane/) is similar to that ob- 
tained from 24-h labeled keratinocyte cell fractions (Fig. 2, 
lane 2). This finding indicates that production of the variant 
species is not an artifact of primary cell culture and produc- 
tion also occurs in skin organ culture. When the labeled skin 
is cultured in nonradioactive medium for an additional 72 h 
there is a diminution of the intensity of the laminin and vari- 
ant species but there is no significant loss of intensity of the 
presumed B1-B2 dimer (Fig. 3, lane 2). Although there is a 
diminution of the intensity of the bands representing the vari- 
ant and laminin, indicating turnover or increased insolubil- 
ization of  these materials to assay procedures, there is no evi- 
dence  of one  form  being  processed  into  the  other.  The 
preserved intensity of the B1-B2 dimer band after a period 
of nonradioactive chase suggests that the dimer may not sim- 
ply  represent incompletely disulfide bonded  laminin,  but 
that it may represent a  stable entity that is sequestered for 
future use either in the assembly of laminin or for some other 
purpose. 
Conditioned medium from human squamous  cell carci- 
noma cultures, and human amniotic fluid both were found 
to be useful for immunoaffinity purification of biochemical 
quantities of laminin and variant. When conditioned squa- 
mous carcinoma cell medium is purified using 2E8-sepha- 
rose and the peak elution fraction is separated by nonreduced 
SDS-PAGE, two high molecular weight laminin species, as 
well as a 150-kD band are stained by Coomassie blue (Fig. 4 
A, lane/).  Because the  150-kD band failed to yield lower 
molecular weight bands on second dimension reduced SDS- 
PAGE (not shown), we interpret this band to represent nido- 
gen. When the band representing the faster migrating variant 
species is excised, separated by second dimension reduced 
SDS-PAGE, and stained by Coomassie blue a broad 220- 
210-kD band as well as a distinct 190-kD band are visualized 
(Fig. 4 B, lane/) analogous to the results obtained with ra- 
diolabeled materials in Fig. 2. Thus Coomassie blue staining 
reveals that stoichiometrically, the B1, B2, and 190-kD chains 
of the faster migrating variant species are present in equal 
amounts. Several minor faintly staining bands of lower mo- 
lecular weight are also noted in Fig. 4 B, lane 1. Similarly 
treated samples were immunoblotted and found to contain 
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fluid and squamous cell carcinoma (SCC)-conditioned medium were used for affinity chromatography with either 2ES-sepharose (monoclo- 
nal antilaminin B2 chain),  or BM165-sepharose (monoclonal antikalinin).  Lanes 1 and 4, 2E8 purified SCC-conditioned medium;  lane 
2, 2E8 purified human amniotic fluid; lane 3, BM165 purified human amniotic fluid; lane 5, BM165 purified SCC-conditioned medium; 
lane 6, laminin from EHS tumor. Samples were separated by nonreduced SDS-PAGE on a 3-5 % acrylamide gradient gel and visualized 
either by Coomassie blue staining (lane 1 ) or Western blotting with polyclonal antilaminin antibody (lanes 2, 3, 4, 5, and 6). Right margin 
indicates Mr ￿  10  -3. L, laminin; and V, variant.  (B) Reduced analysis of laminin and the variant. The nonreduced variant band derived 
from SCC-conditioned medium shown in A, (lane 1, V) was excised from the gel, separated by second dimension SDS-PAGE  under reducing 
conditions  and visualized by Coomassie blue staining (lane 1).  Peak fractions  from BM165-sepharose purification of SCC-conditioned 
medium (lanes 2 and 3) and EHS laminin (lane 4) were separated by SDS-PAGE on a 5% acrylamide gel under reducing conditions and 
transferred to nitrocellulose.  The lane containing the SCC-derived material  (lanes 2 and 3) was cut in half and one half was incubated 
with mAb 545  (lane 2).  The other  half (lanes 3 and 4)  were incubated with polyclonal antilaminin  antibody. Right margin  indicates 
M~  ￿  10  -3. 
several faint lower molecular weight bands  recognized by 
laminin but not kalinin antisera (not shown).  We interpret 
these bands to represent degradation products of K-laminin 
produced during fixation and destaining. 
Nonreduced Western blot analysis (Fig. 4 A) of the peak 
fractions  from conditioned  squarnous  carcinoma cell  me- 
dium and amniotic fluid purified with 2E8-sepharose (Fig. 
4 A, lanes 1, 3, and 5) and BM165-sepharose (Fig. 4 A, lanes 
2  and 4) was done with polyclonal laminin antiserum used 
as primary antibody. Amniotic fluid (Fig. 4 A, lanes 2  and 
3) and squamous carcinoma cell medium (Fig. 4 A, lanes 1, 
4,  and 5)  produce  essentially  identical  results  in  that pu- 
rification over an antilaminin B2 chain column produced two 
nonreduced  species  and  purification  over  an  antikalinin 
column  produced  only  a  single  nonreduced  species.  The 
higher molecular weight nonreduced species (Fig. 4 A, lanes 
1, 2, and 4) comigrates with laminin purified from EHS tu- 
mor (Fig. 4 A, lane 6). Analogous to the results with radioac- 
tive  keratinocyte  medium  in  Fig.  1,  the  lower molecular 
weight nonreduced laminin variant species is the only form 
affinity purified by BM165-sepharose. 
The variant plus kalinin were purified from squamous car- 
cinoma cell culture medium by BM165 affinity chromatogra- 
phy. The disulfide-bond reduced kalinin and variant chains 
were separated by SDS-PAGE using a wide comb, and trans- 
ferred  to  nitrocellulose.  The  nitrocellulose  was  then  cut 
through the center of the electrophoretic lane, and one half 
(Fig.  4  B,  lane  2)  was  Western  blotted  using  mAb  545, 
specific for the laminin B1 chain.  The other half of the lane 
(Fig. 4 B, lane 3) and a second lane containing EHS laminin 
chains  (Fig.  4  B,  lane 4) were blotted with polyclonal an- 
tilaminin. The anti-B1  antibody blots only the upper half of 
the wide band containing the B chains, while both the B1 and 
B2 chains are recognized by the polyclonal serum. This re- 
suit, together with the observation that the variant is immu- 
noprecipitated by anti-B2 mAb (Fig.  1, lane 2) indicates that 
the variant contains authentic B1 and B2 chains. No reaction 
was noted in the position of the 190-kD chain, further verify- 
ing the immunological distinction of this chain from other 
EHS laminin subunits. 
Anti-B2 chain afffinity-purified  variant and laminin from 
squamous cell carcinoma conditioned medium as shown in 
Fig. 4 A, lane 1, were visualized by rotary shadowing. Mole- 
cules  closely  resembling  laminin  were  readily  identified 
(Fig.  5 A). In addition,  molecules shown in Fig.  5 B  were 
frequently seen. These appear as Y-shaped molecules similar 
in size and conformation to the usual cross-shaped laminin 
molecule in that each has one long arm with a large globular 
domain at its distal end, and two short arms each with two 
globular domains at their distal ends.  The Y-shaped mole- 
cule which  we interpret as representing the variant differs 
from the cross shape in that there is no third short arm, al- 
though some images show that there is a small globular do- 
main present at the intersection of the two small arms and 
the long arm. The difference in molecular mass between the 
400-kD A chain and the 190-kD variant chain would there- 
fore need to be contained in the third short arm of the cross. 
The 190-kD substitution for the A chain contributes the large 
globule at the distal end of the long arm similar to the struc- 
ture contributed to laminin by the A chain. The fact that this 
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affinity-purified SCC  medium,  see-conditioned  medium  was 
purified by 2E8-sepharose (antilaminin B2 chain). Pooled peak elu- 
tion fractions analyzed by Coomassie staining and Western blot in 
Fig. 4A (lanes I and 4) were imaged by rotary shadowing EM. (A) 
images representing human laminin. (B) images representing the 
laminin variant. Bar, 50 nm. 
globule is apparently intact in the variant and antibody 4C7 
specifically recognizes this globule on laminin (Engvall et 
al., 1986) is further evidence that this chain is a true substitu- 
tion for the A chain, and not a degradation product. 
A polyclonal antibody was raised in rabbits to the 400-kD 
nonreduced kalinin gel band (Rousselle et al.,  1991).  This 
antibody identified all kalinin chains by Western blotting af- 
ter  disulfide-bond  reduction  (Marinkovich  et  al.,  1992). 
Laminin and variant were purified from squamous  carci- 
noma  cell  medium  using  2E8-sepharose  (anti-B2  chain) 
affinity chromatography, and the product was evaluated by 
SDS-PAGE and Western blotting before and after disulfide 
bond reduction. The nitrocellulose was cut down the center 
of the two lanes, and one half of  each lane was incubated with 
polyclonal anti-laminin,  and the other was incubated with 
the polyclonal antikalinin (Fig. 6 A). The antilaminin serum 
identified both  laminin  and  the  variant before reduction, 
while the antikaiinin serum recognizes only the variant. The 
lack of reactivity of the antikalinin serum with laminin indi- 
cates that the cross-reactivity with the variant must be with 
the 190-kD chain. This cross-reactivity is lost upon disulfide 
bond reduction, and the polyclonai antikalinin serum fails to 
react  with  the  190-kD  chain.  The  immunological  cross- 
reactivity suggests that the chains share conformational epi- 
topes but not sequence specific epitopes. The reactivity of 
the variant with the polyclonal antikaiinin serum indicates 
that the  190-kD variant chain contains epitopes present in 
the 200-kD kalinin chain,  but absent from the laminin A 
chain, supporting the conclusion that the variant chain is not 
a  degradation product of the A  chain.  Comparison of the 
peptides generated from V8 protease digestion (Fig. 6 B) of 
the 190-kD variant chain (V), and the 200-kD kaiinin chain 
(K), each excised from polyacrylamide  gels, indicates nearly 
identical electrophoretic mobilities. In total, these data indi- 
cate that these chains are very similar but not identical. 
Since  the  polyclonal antikalinin  antiserum  cross  reacts 
with the variant, we examined the distribution of  this reactiv- 
ity in skin and in brachial plexus nerve. Similar to results 
seen for kalinin with mAb BM165 (Rousselle et al.,  1991), 
the reactivity was restricted to the basement membrane zone 
of the dermal-epidermal junction of skin (Fig. 7 D), no reac- 
tivity above preimmune serum control was seen in brachial 
plexus nerve (Fig. 7, C and F). The reactivity of the poly- 
clonal  antilaminin  serum  reacts  with  all  basement  mem- 
branes in nerve and skin (Fig. 7, A and B). The nerve was 
also intensely stained with B2 chain specific antibodies (not 
shown) and with antimerosin (Fig. 7 E). Assuming the epi- 
topes recognized by the polyclonal antikalinin serum are ac- 
cessible in tissue, the result indicates that the variant is not 
distributed beyond the dermal-epidermal junction in  skin 
and is not present in peripheral nerve. 
We examined the distribution of  kaiinin, laminin, and vari- 
ant in several other human tissues (Table I). Laminin which 
is specifically recognized by polyclonai laminin antiserum is 
clearly reactive in the basement membranes of skeletal mus- 
cle, blood vessel endothelium, and as seen in Fig. 7, periph- 
eral nerve. Neither kalinin nor variant are present in these 
distributions  evidenced by lack of immunoreactivity with 
mAb  K140  or  with  polyclonal  kalinin  antiserum  which 
recognizes both kalinin and variant.  In trachea, large and 
small intestine, amnion, lung, and skin, polyclonal laminin 
antiserum reacted with all basement membrane containing 
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ant.  (A) Comparative immunobloning  of laminin and the variant. 
Laminin and variant derived from 2E8-Sepharose  (antilaminin B2 
chain) purification of  SCC-conditioned medium, were separated on 
3-5 % acrylamide gels under nonreducing (upper panel) or under 
reducing  conditions  (lower panel)  and electrophoretically  trans- 
ferred to nitrocellulose.  The nitrocellulose containing the lanes of 
both the nonreduced and reduced samples were cut in half. Western 
blot analysis was then completed with both polyclonal laminin an- 
tisera (lej~ halves) and polyclonal kalinin antisera  (right halves). 
(B) Peptide mapping studies using V8 protease.  Bands containing 
the 190-kD subunit of the variant (lane V) derived from polyclonal 
antilaminin  immunoprecipitation  of  radiolabeled  keratinocyte 
medium, and the 200-kD subunit of  kalinin, (lane K) derived from 
BM165 immunoprecipitation of  radiolabeled keratinocyte cell frac- 
tion were excised from gels, partially digested with V8 protease (2 
#g/ml for 30 min, at room temperature)  and the digestion products 
separated  by SDS-PAGE side by side on a  10% acrylamide gel. 
Right margin indicates Mr  x  10  -~. 
structures,  while mAb K140 and polyclonal kalinin antise- 
rum reacted only at areas of epithelial-mesenchymal inter- 
face. These results indicate that, in the tissues examined, the 
variant represents a distinct subset of the total laminin distri- 
bution, and that the distribution of the variant does not ap- 
pear to extend beyond that of kalinin. 
Discussion 
We have identified a  variant of laminin that is restricted in 
its distribution to the basement membrane zone of the der- 
mal-epidermal junction  in  skin,  and  is  absent  in nonepi- 
thelial  basement membranes including  those of peripheral 
nerve, skeletal muscle, and blood vessels. The molecule is 
synthesized by human and bovine keratinocytes, and by a 
squamous cell carcinoma line. The molecule is also present 
in amniotic fluid, as is the epithelial-specific molecule kali- 
nin (not shown). This variant has a 190-kD chain substituted 
for the A chain, which is shorter than the A chain by ,',,240 
kD, and is immunologically unrelated to the laminin A chain. 
Instead, the variant 190-kD chain shows a structural and im- 
munological similarity to the 200/165-kD chain of kalinin. 
Visualization of the variant by rotary shadowing indicates 
that the short arm normally contributed by the A  chain to 
Figure 7. Comparison of laminin distribution  in peripheral  nerve 
and neonatal  foreskin.  Frozen  8-#m-thick  sections of either bra- 
chial plexus nerve from a 20-wk human fetus (,4, C, E, and F), or 
human neonatal foreskin, (B and D) were analyzed by indirect im- 
munofluorescent microscopy. (A and B) Polyclonal antilaminin; (C 
and D) polyclonal antikalinin; (E) mAb 5H2 antimerosin; (F) poly- 
clonal antikalinin,  preimmune serum. Bar,  160 #m. 
laminin is missing in this molecule. However, the substituted 
190-kD chain contributes a  large globule at the end of the 
long arm that appears very much like the domain contributed 
to normal laminin by the A chain. The presence of this large 
Table L  Tissue Survey* 
Antibodies 
Tissue  mAb KI40  Polyclonal kalinin  Polyclonal laminin 
Skin  + *  + *  + 
Trachea  +  *  + *  + 
Large intestine  +  *  +*  + 
Small intestine  +*  +*  + 
Lung  +*  +*  + 
Amnion  + *  + *  + 
Peripheral nerve  -  -  + 
Blood vessels  -  -  + 
Skeletal muscle  -  -  + 
* Indicates  that  staining  was  present  only  at  epithelial-mesenchymal  in- 
terfaces. 
* For this survey indirect immunofluorescent microscopy was performed on 
frozen sections of tissue obtained from a 20-wk (estimated gestational age) nor- 
real human fetus, except the human amnion which was obtained after a term 
delivery, 
Marinkovich et al. K-laminin  701 globule rules out the possibility that the rotary shadowed im- 
ages represent B1-B2 chain dimers, consistent with the ob- 
servation that none of these dimers were detected in the cell 
media preparations. 
A Y-shaped laminin variant has been previously reported 
as a product of rat schwannoma cells.  This molecule lacks 
the laminin A chain and instead contains additional  peptides 
of 130 and 35 kD (Davis et al., 1985). Polyclonal antikalinin 
cross reacts with skin cell-derived variant, but is unreactive 
with peripheral neural tissue suggesting that the skin variant 
is not related to the schwannoma produced variant. Rat astro- 
cytes also synthesize a laminin variant lacking the A chain 
but no  substituted  chain was observed  (Liesi  and Risteli, 
1989). 3T3-L1 adipocytes produce a molecule with a 200-kD 
chain  substituted  for the  A  chain  (Aratani  and Kitigawa, 
1988). The relationship of any of these molecules to the vari- 
ant described here in skin is not yet known. Other laminin 
variants with substituted  A chains include merosin (Ehrig et 
al.,  1990) and mouse heart laminin (Paulsson and Saladin, 
1989),  but both of these molecules  retain the three short 
arms reminiscent of EHS laminin. 
Previous evaluation  of laminin synthesized by both malig- 
nant and nonmalignant keratinocytes showed association of 
laminin with additional glycoproteins (Frenette et al., 1988). 
The data  support the coprecipitation of laminin,  the ker- 
atinocyte variant,  and kalinin by the authors' antilaminin se- 
rum. It is of particular interest that the authors conclude that 
laminin becomes covalently associated with the glycoprotein 
we believe to be kalinin under the culture conditions that they 
use. We have been unable to demonstrate binding of the vari- 
ant to kalinin in materials derived from cell culture as the 
variant is not coprecipitated or copurified with mAb K140 
and kalinin is not coprecipitated or copurified with any of the 
larninin antibodies used in this study (not shown). However, 
when kalinin is isolated directly from human  anmion we 
consistently find kaiinin chains and laminin variant  chains 
which are complexed into a disulfide-bonded aggregate  that 
enters  only  dilute  polyacrylamide  gels  (Lunstrum  et  al., 
manuscript in preparation). 
Woodley et al. (1988) have reported that laminin inhibits 
keratinocyte migration. Recently,  the inhibitory activity has 
been reported to reside in a fragment of the A  chain (D. 
Woodley,  personal communication).  We have  recently  re- 
ported that kalinin is synthesized by growing and migrating 
keratinocytes, but not by confluent keratinocytes (Rousselle 
et al.,  1991).  Since the variant and kalinin appear to be as- 
sociated, it is tempting to speculate that the absence of the 
A chain in the variant may facilitate cell migration, but the 
variant  may  substitute  for  other  functions  provided  by 
laminin. 
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